ReviewThe journal of headache and pain2024
CGRP-targeted medication in chronic migraine - systematic review.
Review in The journal of headache and pain, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Efficacy and safety of Chinese botanical drug decoctions for migraine: a Bayesian network meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis.Frontiers in neurology · 2024Pooled it
- A randomized, double blind, placebo-controlled pilot study to assess the efficacy of erenumab in individuals with temporomandibular disorder.Journal of oral & facial pain and headache · 2025Trial
- Migraine and Obesity: From Shared Mechanisms to Therapeutic Strategies.Neurology and therapy · 2026Review
- Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.Pain and therapy · 2026Review
- Calcitonin gene-related peptide concentration in cerebrospinal fluid and serum in horses affected by trigeminal-mediated headshaking.Equine veterinary journal · 2026Article
- CGRP-targeted therapies for migraine and the risk of infection.Internal and emergency medicine · 2026Review
- A highly efficient method to differentiate CGRP-expressing peptidergic nociceptors from human induced pluripotent stem cells.Stem cell reports · 2026Article
- Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.The journal of headache and pain · 2026Article
- Global, regional, and national burden of migraine in postmenopausal women: a 32-year analysis from the global burden of disease study 1990-2021.Journal of oral & facial pain and headache · 2026Article
- Functional characterisation of dura mater αCGRP degradation fragments at vascular, immune, and CGRP receptor targets.The journal of headache and pain · 2026Article
- PVNAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- An exploration of possible future non-pharmacological multidisciplinary treatments to potentiate withdrawal strategy and recovery from medication overuse headache (MOH): a narrative review.Journal of oral & facial pain and headache · 2026Review
- Use of CGRP Monoclonal Antibodies in Japan, South Korea, and Taiwan: A Narrative Review.Current pain and headache reports · 2026Review
- Trends in migraine-specific medication consumption: a multinational analysis of 73 countries based on IQVIA-MIDAS database, 2015 to 2024.The journal of headache and pain · 2026Article
- A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence.European journal of neurology · 2026Observational
- Glymphatic System Dysfunction in Central Nervous System Diseases.CNS neuroscience & therapeutics · 2026Review
- Diagnosing migraine from genome-wide genotype data: a machine learning analysis.Brain : a journal of neurology · 2026Article
- OnabotulinumtoxinA for chronic migraine: A real-life multicenter study of 479 patients.Therapeutic advances in neurological disorders · 2026Article
- Efficacy of Erenumab in Patients With Treatment-Resistant Chronic Migraine and Medication Overuse Headache.Neurosciences (Riyadh, Saudi Arabia) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic migraine is a highly debilitating condition that is often difficult to manage, particularly in the presence of medication overuse headache. Drugs targeting the calcitonin gene-related peptide (CGRP), or its receptor have shown promising results in treating this disorder.
methodsWe searched Pubmed and Embase to identify randomized clinical trials and real-world studies reporting on the use of medication targeting the calcitonin gene-related peptide in patients with chronic migraine.
resultsA total of 270 records were identified. Nineteen studies qualified for the qualitative analysis. Most studies reported on monoclonal antibodies targeting CGRP (anti-CGRP mAbs), that overall prove to be effective in decreasing monthly migraine days by half in about 27.6-61.4% of the patients. Conversion from chronic to episodic migraine was seen in 40.88% of the cases, and 29-88% of the patients stopped medication overuse. Obesity seems to be the main negative predictor of response to anti-CGRP mAbs. There is no evidence to suggest the superiority of one anti-CGRP mAb. Despite the lack of strong evidence, the combination of anti-CGRP medication with onabotulinumtoxinA in chronic migraine is likely to bring benefits for resistant cases. Atogepant is the first gepant to demonstrate a significant decrease in monthly migraine days compared to placebo in a recent trial. Further, anti-CGRP mAb and gepants have a good safety profile.
conclusionThere is strong evidence from randomized trials and real-world data to suggest that drugs targeting CGRP are a safe and effective treatment for chronic migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.